Warning: include_once(/home/aspenxadmin/public_html/files/EIT_html_excerpt.php): failed to open stream: No such file or directory in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-1.php on line 5

Warning: include_once(): Failed opening '/home/aspenxadmin/public_html/files/EIT_html_excerpt.php' for inclusion (include_path='.:/opt/alt/php72/usr/share/pear') in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-1.php on line 5

Warning: include_once(/home/aspenxadmin/public_html/files/EIT_html_excerpt.php): failed to open stream: No such file or directory in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-2.php on line 5

Warning: include_once(): Failed opening '/home/aspenxadmin/public_html/files/EIT_html_excerpt.php' for inclusion (include_path='.:/opt/alt/php72/usr/share/pear') in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-2.php on line 5

Warning: include_once(/home/aspenxadmin/public_html/files/EIT_html_excerpt.php): failed to open stream: No such file or directory in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-3.php on line 5

Warning: include_once(): Failed opening '/home/aspenxadmin/public_html/files/EIT_html_excerpt.php' for inclusion (include_path='.:/opt/alt/php72/usr/share/pear') in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-3.php on line 5

Warning: include_once(/home/aspenxadmin/public_html/files/EIT_html_excerpt.php): failed to open stream: No such file or directory in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-4.php on line 5

Warning: include_once(): Failed opening '/home/aspenxadmin/public_html/files/EIT_html_excerpt.php' for inclusion (include_path='.:/opt/alt/php72/usr/share/pear') in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-4.php on line 5

Warning: include_once(/home/aspenxadmin/public_html/files/EIT_html_excerpt.php): failed to open stream: No such file or directory in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-5.php on line 5

Warning: include_once(): Failed opening '/home/aspenxadmin/public_html/files/EIT_html_excerpt.php' for inclusion (include_path='.:/opt/alt/php72/usr/share/pear') in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-5.php on line 5

Warning: include_once(/home/aspenxadmin/public_html/files/EIT_html_excerpt.php): failed to open stream: No such file or directory in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-6.php on line 5

Warning: include_once(): Failed opening '/home/aspenxadmin/public_html/files/EIT_html_excerpt.php' for inclusion (include_path='.:/opt/alt/php72/usr/share/pear') in /home/aspenxadmin/public_html/wp-content/themes/magzilla/framework/vc_shortcodes/module-6.php on line 5

Warning: in_array() expects parameter 2 to be array, string given in /home/aspenxadmin/public_html/wp-content/plugins/ajax-search-pro/includes/classes/actions/class-asp-indextable.php on line 156

Warning: get_class() expects parameter 1 to be object, null given in /home/aspenxadmin/public_html/wp-content/plugins/real-media-library/inc/comp/WPML.class.php on line 32
Project Alert | Aspen Xchange

Project Alert

CytoImmune Therapeutics and Biosimilar Sciences have made public plans to establish operations in Puerto Rico to develop their biotechnology products. For its part CytoImmune Therapeutics will invest $28 million for a facility to engage in developing cancer immunotherapy solutions. While Biosimilar Sciences will invest $200 million to establish a state-of-the-art biotech facility for the development of biosimilar products, including a COVID-19 vaccine, new cell and gene therapy, biologics, clinical studies, and other recombinant biotechnologies.
Learn More

High Purity New England (HPNE) announced this week that they have officially acquired their third facility, expanding their total footprint to include more than 100,000 square feet under roof. The new building, which is located on the same street as their two current facilities, will be used to create their sixth state-of-the-art clean room environment for manufacturing, a new distribution center and a new lab, as well as additional office space. This comes exactly two years after their expansion into their second facility, a former Alexion office building, creating a small corporate campus along Thurber Boulevard in Smithfield, Rhode Island.
Learn More

Cambrex will invest $50 million to add four active pharmaceutical ingredients (API) facilities at its Charles City, Iowa, small-molecule drug site and expand capacity by 30%. The new facilities—three of which will handle "large-scale" manufacturing, with the fourth dedicated to "mid-scale" production—are set to go online in early 2022. In total, the Charles City site will eventually employ 400 workers. 
Learn More

Tonix Pharmaceuticals, a clinical-stage biopharmac company based in Chatham, New Jersey has purchased a 44-acre site in Hamilton, Montana to build a vaccine development and commercial-scale manufacturing facility. The project comes on the heels of Tonix’s purchase of a 40,000-square-foot facility in Massachusetts to house its Advanced Development Center for development and manufacture of vaccines. Both sites are expected to support development and production of Tonix’s vaccine candidates, including potential products for horsepox, COVID-19, smallpox, monkeypox and more. Tonix expects to break ground on the Montana site later this year.
Learn More

Taysha Gene Therapies will add more than 200 jobs as part of an expansion in RTP. The company, based in Dallas, chose the Triangle over Dallas, Texas, for a 160,000 square foot facility which will serve as its manufacturing site. It will invest $75 million as part of the expansion. North Carolina’s Economic Investment Committee approved a state benefits package of more than $5 million for the project at a meeting earlier this week. Taysha joins a growing number of companies in the Triangle area focused on gene therapies. The site is expected to be completed and conducting hiring in the next three years.
Learn More

MSD has announced plans to builds a new research facility next to a biologics medicines plant it acquired in Dunboyne, Co Meath earlier this year. The 120 acres site was acquired by Takeda with the acqusiiton of Shire with the latter having invested $460 million ($375 million euros) prior to it being sold to MSD in August '2020. The new research facility, which will be built alongside the existing manufacturing facility, is expected to be ready for use by the end of 2023.
Learn More

Adverum Biotechnologies will invest $82.8 million for a new gene therapy manufacturing facility in Durham County, North Carolina. The new facility, which will encompass 174,000 square-feet, will include no fewer than four 1,000 liter bioreactors at the outset and be enabled to support future expansion. For its part, the state of North Carolina and local governments have committed up to $9 million in incentives to Adverum which plans to create 200 jobs. According to published reports the new cGMP manufacturing facility will be ready to manufacture commercial product by 2023.
Learn More

Civica has announced plans to invest $124.5 million to establish its North American manufacturing headquarters operation in Petersburg, Virginia. The company plans to construct a 120,000-square-foot manufacturing facility in Petersburg, where it will manufacture vials and syringes of injectable medicines used for COVID- 19 patient care, emergency rooms and surgeries, as well as the treatment of serious infections and hypertension. The new plant is part of a larger federal strategy to establish an American manufacturing hub and supply chain for generic medicines and pharmaceutical ingredients needed to treat COVID-19.
Learn More

Northway Biotech has opened its new 30,000-square-foot process development and cGMP manufacturing site in Waltham, Massachusetts. From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian-based biologics. The cGMP biomanufacturing suite will house 500 L microbial and 2,000 L mammalian bioreactors and be operational in Q4 2021, representing a capital investment program worth $40 million.
Learn More

Northway Biotech has opened its new 30,000-square-foot process development and cGMP manufacturing site in Waltham, Massachusetts. From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian-based biologics. The cGMP biomanufacturing suite will house 500 L microbial and 2,000 L mammalian bioreactors and be operational in Q4 2021, representing a capital investment program worth $40 million.
Learn More

Modavar Pharmaceuticals recently opened a brand new, state-of-the-art, 22,000 square foot manufacturing facility in Frederick, Maryland, adding a new life science company to the blossoming Frederick biotech hub. Modavar develops and manufactures its own generic drug formulations and co-develops products with organizations via its Contract Manufacturing arm. The company currently has six approved Abbreviated New Drug Applications (ANDA) and 14 ANDAs filed with the U.S. FDA. 
Learn More

YMC America will expand its operations into the YMC Devens, MA facility beginning February 1st, 2021. This move from its existing location in Allentown, PA will provide more space for inventory and a larger employee base. The move seeks to retain the majority of YMC America employees. The YMC Devens, MA facility is the 32,000 ft2 (2,900 m2) R&D and manufacturing site of the former LEWA Process Technologies, which YMC acquired in 2019. The YMC Devens location is simultaneously establishing a new lab facility in a recently acquired building adjacent to the current site. This lab facility will support the heritage YMC America products, and serve as a center for conducting short and long-term studies as well has hands-on training.
Learn More

Abzena has announced the addition of a 6th Global site that will augment cGMP manufacturing capacity for mammalian biologics. This expansion is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas. The new facility will be based in the United States and will accommodate phase 3 and commercial manufacturing.  A phased approach to construction will initially allow 4 modular suites with each suite including up to two 2000L bioreactors, followed by the addition of two further 2000L suites.  Additionally, the site will be equipped to handle existing and new advances in manufacturing such as continuous manufacturing and perfusion with manufacturing commencing in mid-2022.
Learn More

Adverum Biotechnologies will invest $82.8 million for a new gene therapy manufacturing facility in Durham County, North Carolina. The new facility, which will encompass 174,000 square-feet, will include no fewer than four 1,000 liter bioreactors at the outset and be enabled to support future expansion. For its part, the state of North Carolina and local governments have committed up to $9 million in incentives to Adverum which plans to create 200 jobs. According to published reports the new cGMP manufacturing facility will be ready to manufacture commercial product by 2023.
Learn More

Fujifilm Corporation is investing more than $2 billion to establish a new large-scale cell culture production site in the U.S. This new facility will offer large-scale cell culture manufacturing of bulk drug substance with 8 x 20,000L bioreactors (physical volume), with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand. In addition to drug substance manufacture, the facility will also provide commercial scale, automated fill-finish and assembly, packaging and labeling services. The new site will be built within the vicinity of an existing Fujifilm site, and is scheduled to begin operations in the spring of 2025. Fujifilm Diosynth Biotechnologies will operate the new facility.
Learn More

Taysha Gene Therapies will add more than 200 jobs as part of an expansion in RTP. The company, based in Dallas, chose the Triangle over Dallas, Texas, for a 160,000 square foot facility which will serve as its manufacturing site. It will invest $75 million as part of the expansion. North Carolina’s Economic Investment Committee approved a state benefits package of more than $5 million for the project at a meeting earlier this week. Taysha joins a growing number of companies in the Triangle area focused on gene therapies. The site is expected to be completed and conducting hiring in the next three years.
Learn More

Tonix Pharmaceuticals, a clinical-stage biopharmac company based in Chatham, New Jersey has purchased a 44-acre site in Hamilton, Montana to build a vaccine development and commercial-scale manufacturing facility. The project comes on the heels of Tonix’s purchase of a 40,000-square-foot facility in Massachusetts to house its Advanced Development Center for development and manufacture of vaccines. Both sites are expected to support development and production of Tonix’s vaccine candidates, including potential products for horsepox, COVID-19, smallpox, monkeypox and more. Tonix expects to break ground on the Montana site later this year.
Learn More

FUJIFILM will invest approximately $40 million in FUJIFILM Diosynth Biotechnologies to establish a new process development and manufacturing facility for viral vectors and advanced therapies in Watertown, Massachusetts. The new facility is scheduled to begin process development operations in fall 2021 and will expand FUJIFILM Diosynth Biotechnologies’ manufacturing capacity to support the growing viral vector sector. The new facility will house experimental and analytical equipment for viral vector and advanced therapy process development, with contract manufacturing services for early phase clinical trials beginning at the site in fall 2023.
Learn More

Shanghai Pharma has kicked off the construction of a $1.18 billion biopharmaceutical industry campus. The project will cover 3.2 million square feet constructed in two phases, with 1 million square feet of floor space allocated for the first phase and 2 million square feet for the second. The site will dedicate 538,000 square feet to focus on cutting-edge sectors such as research related to cell and gene therapy. While 861,000 square feet will be allocated for the manufacturing of therapeutics antibodies. According to published reports the latter will involve no fewer than 120,000 liters of bioreactor capacity.
Learn More

MSD has announced plans to builds a new research facility next to a biologics medicines plant it acquired in Dunboyne, Co Meath earlier this year. The 120 acres site was acquired by Takeda with the acqusiiton of Shire with the latter having invested $460 million ($375 million euros) prior to it being sold to MSD in August '2020. The new research facility, which will be built alongside the existing manufacturing facility, is expected to be ready for use by the end of 2023  
Learn More

Takeda has announced that it has started construction of a plant in Singen, Germany, dedicated to manufacture the drug substance for its dengue vaccine candidate by 2025. The company is investing an additional $90 million (74 million euros) in the site, reaching a total investment of over $245 million for vaccine production in Singen. This means that everything from the manufacturing of the active drug substance to the production of the vaccine, to the filling and final packaging, to worldwide shipping will take place in one location.
Learn More

The University of Arizona officially opened its new biotech-focused business incubator.
The UA Center for Innovation at Oro Valley offers 4,000 square feet for new businesses and startups to develop technologies and programs in the bioscience fields. Some developments officials expect to see are vaccine therapies, drug discoveries, therapeutics, and biomedical imaging. Thanks to this new space, researchers will have the tools and guidance they need to succeed. “These biotech companies can’t do this work in their garage. They don’t have access to the many tens of thousands of dollars of equipment, procedures, and physical resources that we have here in the lab,” UACI Executive Director, Eric Smith said. The first tenant in the new space is TheraCea Pharma.
Learn More

Takeda has formally launched the expansion of its production line at its Bray facility in Ireland. The expansion will add production, packaging and shipping for two oncology products to the sites manufacturing portfolio. This addition of oncology production brings a new therapeutic capacity to the site. Commercial production at the site of these new products is expected to begin in early 2020.
Learn More

Lonza has announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated conjugation suites, totaling roughly 16,000 sq. ft. in area, for the commercialization of antibody-drug conjugates (ADCs) at its site in Visp, Switzerland. The high throughput bioconjugation suites will be capable of handling highly-potent materials for cancer therapies and will initially manufacture two therapies. The new dedicated facility will employ around 200 staff, with operations expected to start from the end of 2022.
Learn More

KBI Biopharma is establishing a new commercial manufacturing facility in Research Triangle Park, NC. The $150 million, 140,000-sq-ft facility is expected to be fully operational in early 2022. The site will support over 200 technical positions in operations and quality assurance. KBI is co-investing in the facility with an undisclosed pharmaceutical partner to support manufacturing of their therapeutic protein targets. The current cGMP biologics manufacturing site will also be used as a commercialization option for KBI's existing and future partners. The location will house up to six 2,000-L, single-use bioreactor systems, and associated harvest and purification equipment.
Learn More

AGC Biologics has announced that it will increase the production capacity of its Copenhagen facility. AGC Biologics will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors, labs and office space. The total investment for this expansion is estimated to be approximately $195M (€160M) and the start of operation is scheduled for 2023. This expansion will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen, enabling AGC Biologics to meet the needs of the market. The new building will have a total floor area of approximately 205,000 sq.ft. (19,000m2) and is an important part of AGC Biologics’ global expansion plan.
Learn More

Revance Therapeutics officials said in a Securities and Exchange Commission filing that they have signed a lease for the top floor of the just-opened Gulch Union office building at 1222 Demonbreun St. in Nashville, Tennessee. The company, which markets Botox alternatives and other neuromodulator therapeutics, has leased nearly 41,000 square feet it expects to move into during the first quarter. Until then, it is taking up some temporary space in Gulch Union. Revance's lease covers all of 1222's 20th floor and about a third of the building's ninth floor and could house more than 110 people by early 2022. The company's contract is for 12.5 years and comes with a seven-year extension option. Developer Endeavor Real Estate Group has committed up to $5 million worth of tenant improvements for Revance's space.
Learn More

King Street Properties has plans to develop a 45-acre biomanufacturing campus in Devens, with five buildings totaling 700,000 square feet. It's all part of a new business line, called Pathway, for the life-science focused real estate developers. King Street has assembled a combined 45 acres in Devens, including two parcels on Jackson Road from quasi-public agency MassDevelopment and a third piece of land in a private sale. Lynch anticipates a $500 million investment to develop the five-building campus. That’s about $150 million in hard costs and $350 million to fit out the properties with the highly sophisticated technical equipment needed to make drugs that can go into the human body, Lynch said.
Learn More

Halda Therapeutics, a Branford-based drug discovery company, has signed a lease for 9,800 square feet of lab and office space in Science Park. The company was founded by professor of molecular, cellular and developmental biology Craig Crews and received funding from venture capital firms in early 2019, according to the company’s website. Company representatives told the News that Yale students are interning for Halda already and that relocating in the first quarter of 2021 would increase opportunities for all New Haven residents.
Learn More

The Lundquist Institute’s proposal for a 15-acre biotech park near Torrance has been approved by the Los Angeles County Board of Supervisors. The project will sit on the campus of county-owned Harbor-UCLA Medical Center. The institute was granted a 55-year ground lease on the site with two 20-year extension options to develop the campus. The Lundquist institute already occupies space on the campus, where it opened BioLabs at the Lundquist last year. The site is now home to more than 20 early stage startups. The fact that space filled up so quickly, David Meyer, president and chief executive of the Lundquist Institute said, “speaks to the need for space for startup companies in L.A. County.” The new Lundquist project will allow companies to move from BioLabs to a larger property with permanent office space and expanded services.
Learn More

Celltrion has unveiled its plan to build its third plant and a global biotechnology research center in Songdo, Incheon. The company will build a 60,000-liter biopharmaceutical plant to build a multi-type production and supply system and a one-stop research center for complex R&D, process development, and clinical practice. "We will invest 500 billion won ($453.3 million) into building the plant and research center, completing the research center in July 2022 and the third plant in May 2023. The third plant will start operation from June 2024," Celltrion said. When the third plant is completed, Celltrion will have a production capacity of 250,000 liters annually, a sharp increase from 190,000 liters at the two existing plants. The proposed factory will install a total of eight 7,500 liters incubators, as the company is set to respond flexibly to the production of its biopharmaceuticals as its portfolio widens.
Learn More

Headquartered in Nashville, August Bioservices will invest $64.7 million and create 180 jobs over the next five years. The first phase of the project, which will be completed in late 2021, will involve the targeted expansion of August Bioservices’ existing Nashville facility, adding high-value technologies such as lyophilization and terminal sterilization to its existing cGMP fill and finish manufacturing capabilities. The second phase of the project will see August Bioservices construct a new, state-of-the-art, drug development and manufacturing facility that will feature multiple high-speed production lines capable of delivering commercial scale throughput across a wide array of sterile injectables containers, including vials, IV bags and prefilled syringes.
Learn More

Corden Pharma has made a strategic decision to expand their current offering with the manufacturing of larger quantities of non-GMP peptides. Aside from increasing available lab space by 25%, a dedicated explosion proof area will be added, which is supported by a tailored tank farm. This will allow for the introduction of regular solvents, as well as compatibility with their green peptide manufacturing.
Learn More

Cambrex will invest $50 million to add four active pharmaceutical ingredients (API) facilities at its Charles City, Iowa, small-molecule drug site and expand capacity by 30%. The new facilities—three of which will handle "large-scale" manufacturing, with the fourth dedicated to "mid-scale" production—are set to go online in early 2022. In total, the Charles City site will eventually employ 400 workers. 
Learn More

Eisai has made a $15.2 million investment to fund two new packaging lines and create new jobs at its Hatfield production plant in Hertfordshire. Following a succession of approvals and reimbursements across the world for its cancer therapy, Lenvima (lenvatinib), Eisai is now expanding its facilities to triple product output within the next three years and is targeting a four-fold increase by 2025 to meet global demand.
Learn More

Turkish pharmaceuticals manufacturer Pharmactivecplans to establish a biotechnological pharmaceutical factory in Turkey following the clinical trial results of five biotechnological drugs it is developing in partnership with South Korean firm Polus. Pharmactive Technical Operations General Manager Fatih Elay said in a report published by Turkish daily Dünya that the production process of five biotech drugs, which they developed jointly with Polus, was completed, and clinical trials were initiated. He said that if the results came back positive from those trials, they will make the factory investment in Turkey and build a factory that mirrors the one they currently have in Incheon.
Learn More

IQHQ, a biotech-focused real estate investment group, acquired the bulk of the development site known as Manchester Pacific Gateway for $230 million, according to public records. The purchase price, which was not disclosed at the time of the late September transaction, underscores the scope of the biotech office developer’s ambitions, which is to remake its new waterfront holdings into a $1.5 billion life science city known as the San Diego Research and Development District, or RaDD. IQHQ was started a year ago by esteemed life science builder Alan Gold, who founded BioMed Realty Trust and sold it to Blackstone Group in a transaction valued at $8 billion. The firm’s focus is on creating unrivaled life science centers in four markets: San Diego, San Francisco, Boston and the United Kingdom. The San Diego endeavor has been characterized as an industry-leading bet on major biotech businesses eventual interest in the downtown market.
Learn More

Holiferm has announced plans to establish a pilot plant at the Sci-Tech Daresbury campus in Halton, UK. This comes after the local government in Liverpool awarded a $528,000 grant. The plan is to conduct a proof of concept with the pilot plant which would lead to a full commercial manufacturing site in Wirral. 
Learn More

BioAgilytix has made public plans to invest $61 million to expand their site in Durham, North Carolina. The decision comes after the company had considered expanding in Massachusetts but were awarded financial incentives by state and local government. The expansion is expected to create hundreds of new jobs at the site.
Learn More

Ginkgo Bioworks has signed a 38,759-square-foot life sciences lease at 10 Wilson Road in the Cambridge area of Boston. The new space is located within The Quad, a four-building, 510,000-square-foot campus that is being developed in phases by The Davis Companies.
Learn More

After establishing a manufacturing foothold in Belgium as part of a $315 million deal earlier this year, Catalent is now picking up an adjacent site to add to its booming portfolio. Catalent has acquired a 31,000-square-foot cell and gene therapy facility in Gosselies, Belgium, from Bone Therapeutics' Skeletal Cell Therapy Support SA subsidiary to add to its growing "center of excellence" in the area. Once the $14 million buyout closes in November, Catalent will continue to produce Bone's investigational cell therapy Allob on-site, and Catalent will add the employees there to its workforce. The facility houses quality control and development labs, warehouse space, grade C and B cleanrooms and "equipment as well as land for further development," Catalent said.
Learn More

Qilu Pharmaceutical Co. has again selected ABEC to rapidly expand production capacity at their cGMP manufacturing facility in Jinan, Shandong, China. ABEC is delivering several sets of large-scale, stainless-steel, cell-culture bioreactors. To support a robust monoclonal antibody product pipeline, Qilu currently operates the largest total bioreactor capacity in China, and this expansion builds on that leadership. The new bioreactor trains will be installed at Qilu’s Biopharmaceutical Industrial Park, which is one of the largest biopharmaceutical industrial parks in China. Since 2009, Qilu has continuously chosen to partner with ABEC based on excellent process performance, consistent adherence to schedule, and long-term service and support. Learn More

Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, has signed a 10 year lease on 138,000 square feet at 200 West Street in Waltham, Massachusetts. The site, currently being redeveloped by BXP into lab space, is expected to be completed in 2021. 200 West Street features a variety of modern lab spaces, including cold rooms and pilot labs, as well as chemistry and biology labs. The redevelopment site also features an additional roughly 130,000 square feet of developable life science space. With this deal Translate Bio joins a growing list of leading biotech’s that call Waltham home. Learn More

New England Biolabs® (NEB®) has selected ABEC to expand production capacity at their manufacturing facilities in Ipswich and Rowley, MA. NEB, an international leader in the discovery and production of recombinant proteins for molecular biology applications, will utilize multiple customized stainless-steel fermenters for high-density Escherichia coli fermentation. With expected delivery of the ABEC 400L and 1000L fermenters by mid-2021, the expansion will enable NEB to continue to increase their product offerings. ABEC’s extensive experience, complete in-house capabilities, and long-term credibility will ensure NEB’s ongoing ability to manufacture high-quality products with proven lot-to-lot consistency. Learn More

Ultragenyx Pharmaceuticals has announced that it plans to build a new large-scale gene therapy manufacturing facility in Bedford, Massachusetts. The planned Phase I facility will encompass 100,000 square feet and provide important internal capacity to develop and manufacture supply of Ultragenyx’s gene therapies for both clinical stage and approved products. The facility will be able to support two independent manufacturing suites with a capacity of 30 runs per year. Construction of the new facility has begun and is expected to be complete in 2023. Ultragenyx already controls land and development rights for an additional 86,000 square feet of Phase II expansion on-site which could be used to double capacity if needed. Learn More

Lonza has inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp, Switzerland site. This first manufacturing suite handles compounds with occupational exposure levels down to 1ng/m3 and is dedicated to the manufacturing platform for ADC drug linkers. This expansion underlines the strategic position of ADCs in the Lonza portfolio, with the company developing and producing all components of these increasingly important cancer treatments: cytotoxic payloads, antibodies and the required linkers on one site. Learn More

Revance plans to lease a 79,000 square-foot single-tenant building on Campus Drive in Marlborough, Massachusetts. The new site would be home to both aseptic filling and R&D operations. Estimates have the initial capital investment at upwards of $115 million. Revance Therapeutics will create and maintain 76 permanent, full-time jobs at the site. The company has been in talks with city leaders about opening a facility for the past few months. It is understood that the last remaining hurdle is a 15-year tax increment financing deal which is expected to be approved in the coming weeks. Learn More

Pfizer is set to invest roughly $350 million in its three Irish manufacturing sites in Ringaskiddy, Dublin and Kildare. The investment will provide additional manufacturing and laboratory capacity, creating 300 roles over the next two to three years. The roles being created comprise a wide array of highly skilled positions such as engineers, scientists, technicians, and chemists. Part of this investment will allow the construction of a site at Ringaskiddy to manufacture pharmaceutical compounds for the company’s clinical trials across the globe. It will also mark the shift from manufacturing to support the earlier phases of medicine development. Learn More

Sai Life Sciences, one of India's fastest growing CRDMO's, unveiled plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 square foot facility and an augmented team of 170 biologists. The new facility will house expanded in vitro and in vivo biology services, DMPK and toxicology capabilities with the first set of labs scheduled to open in March 2021. Learn More

Aphena Pharma Solutions has completed its $7 million facility expansion and renovation in Easton, MD. The newly renovated, 30,000-sq.-ft. facility and three large blending suites are open for new pharmaceutical business supporting liquids, creams, gels and suspensions. Housed in the new blending suites are two new Feldmeier 1,000-gallon mixing tanks and a sister 100-gallon tank, which offer center agitation mixing and dual alternate directional side sweeps for scale-up and registration batches. In addition, the tanks are jacketed for heat and chilling and are pressurized for powder mixing. Learn More

Sartorius is expanding its presence in Massachusetts with a North American Customer Interaction Center. Sartorius will be opening first units of the new 40,000-square-foot Customer Interaction Center in Marlborough in early 2021. "With our new site in Marlborough, we will be optimizing factory acceptance testing and commissioning of new bioprocess equipment supplied to the North American market. This investment will translate into tangible benefits for our customers, employees, suppliers, and the local community," said the President of Sartorius North America, Mary Lavin. Learn More

Sartorius is expanding its presence in Massachusetts with a North American Customer Interaction Center. Sartorius will be opening first units of the new 40,000-square-foot Customer Interaction Center in Marlborough in early 2021. "With our new site in Marlborough, we will be optimizing factory acceptance testing and commissioning of new bioprocess equipment supplied to the North American market. This investment will translate into tangible benefits for our customers, employees, suppliers, and the local community," said the President of Sartorius North America, Mary Lavin. Learn More

ABEC has announced that it will be providing CSR single-use mammalian cell culture and microbial fermentation systems, including the industry's first 6,000L single-use bioreactor, to BioInno Bioscience's new contract development and manufacturing facility in Suzhou, Jiangsu, China. The facility is expected to be operational by mid-2021. BioInno's facility will utilize single-use technologies to enable multi-product flexibility and rapid time to market, and ABEC's CSR systems will also be used for plasmid DNA and viral vector manufacturing. Learn More

WuXi Biologics has announced the opening of a new process development and testing lab in King of Prussia, Pennsylvania. WuXi Biologics partnered with Discovery Labs and Integrated Project Services (IPS) to lease and renovate the 33,000-square-foot facility, which will include a development lab and shipping, delivery and storage space. The company has already hired more than 50 highly skilled employees to work at the facility, with plans to hire at least 50 more in the coming months. The King of Prussia site is the first of three WuXi Biologics facilities being opened in the United States. Learn More

The City of Vacaville, California has signaled the start of the next generation of development of its world class biomanufacturing cluster by announcing plans to expand it on approximately 300 acres adjacent to existing facilities and to name the entire zone the California Biomanufacturing Center. At the same time, the city announced the creation of the California Biomanufacturing Center, Inc., a nonprofit that will accelerate the growth of the sector in Vacaville by working with industry and academic partners to ensure Vacaville remains a place for biomanufacturing to flourish and to ensure that the industry and community thrive together. Learn More

A startup formed this past summer plans to spend $60 million to build a 60,000-square-foot facility in Fishers, Indiana, as it prepares to offer contract development and manufacturing services to the biopharmaceutical industry. Incog BioPharma Services intends to break ground on the new facility and headquarters as early as December and become fully operational in the first half of 2022. The company will focus its efforts on sterile injectible drugs, which have run into manufacturing issues and shortages in recent years. The company plans to begin hiring early next year and expects to have a workforce of more than 65 within the next two years, ramping up to 150 by the end of 2024. Learn More

AbSci has raised $65 million in equity, proceeds from which will be used to increase production capacity, expand AbSci's facility and support research and development, the company said in its announcement. AbSci's protein printing technology expedites the biopharmaceutical discovery and development process. The news comes about 10 months after AbSci raised a $10.4 million round and $5 million in debt. The company had doubled its space in downtown Vancouver and installed new equipment. AbSci's current raise is the largest by a Portland-area biotech company this year. Learn More

Thermo Fisher Scientific has announced plans to build a $130 million sterile filling plant in Singapore, extending its capacity to develop and manufacture therapies and vaccines to the Asia-Pacific region. The plant, when operational in 2022, will have the capacity to make up to 30 million sterile doses a month and employ more than 300 people. Thermo Fisher said the new plant will initially include a high-speed sterile line approved for live virus filling, followed by an additional line for standard fill/finish. The facility will also have cleanroom capacity, labs, warehousing and offices to support production, the company said. Learn More

UCB has signed an agreement to acquire a new 47-acre campus for its UK operations. The acquisition of the site in Windlesham, Surrey, formerly Eli Lilly's second largest research site in the world, is anticipated to be completed in November 2020. The site will undergo state-of-the-art refurbishment prior to UCB relocating from its current UK headquarters in Slough, Berkshire. UCB's projected investment in the UK, including this site, will be roughly $1.3 billion over five years and the transition to this new facility will support more than 650 high-value jobs in scientific research, translational medicine, clinical development, early manufacturing and commercial roles. Learn More

Merck, known as MSD outside the United States and Canada, this week announced it will construct a new manufacturing facility to significantly expand its production capacity for TICE® BCG, a medicine for the treatment of certain forms of bladder cancer. Once this new facility is fully operational, which could take upwards of 5 years, it will triple current manufacturing capacity. The new facility will be part of the existing Maurice R. Hilleman Center for Vaccine Manufacturing in Durham, North Carolina. While no word yet on the size or cost of the new facility, it is expected to create about 100 new jobs locally. Learn More

In May, NewAge Industries, the parent company of AdvantaPure, bought two of three units in a building within seven miles of its headquarters. NewAge recently purchased the remaining unit and now owns the entire seven-acre property consisting of over 90,000 sq. ft. of future production, warehouse and office space. NewAge recently started Phase 1 of renovations and is preparing areas for clean room manufacturing and offices for production and quality department personnel. The company will use the facility as an additional site for the manufacture of AdvantaSil® silicone tubing and braid reinforced hose, weldable and sealable AdvantaFlex® thermoplastic elastomer (TPE) tubing, and Single-Use molded tubing assemblies. Learn More

NeuBase Therapeutics has signed a 10-year lease for lab and office space at the Pittsburgh Tech Center. The site, part of the New Riviera project being developed by Burns Scalo is a high-end office project on the banks of the Monongahela river in Pittsburgh, Pennsylvania. As of this writing, NeuBase is planning to take occupancy of its new headquarters in March of 2021. No word yet on just how much of the 160,000 sq. ft. office building NeuBase has leased. It is known that other tenants include BlueSphere Bio and the Hillman Cancer Center. Learn More

Forge Biologics has secured $40 million to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021, and for the development of a novel gene therapy pipeline. Forge Biologics is a viral vector CDMO and therapeutics developer, located in a 175,000 sq. ft. facility in Columbus, Ohio. This facility, referred to as The Hearth, is home to a custom-designed cGMP facility dedicated to AAV viral vector manufacturing, currently capable of up to 50L scale research and toxicology grade AAV manufacturing. By mid-2021, The Hearth will host end-to-end cGMP AAV manufacturing services at 500L scale, enabling biotech and pharma clients the ability to accelerate their gene therapy programs from pre-clinical development through clinical and commercial stage manufacturing. Learn More

Abzena has invested $60 million into a new facility for late phase and commercial cGMP manufacturing. The new roughly 50,000 sq ft 'Lusk' facility, at the company's site in San Diego, CA, houses a process development laboratory and two new cGMP manufacturing cleanrooms for 500L and 2,000L scale in Sartorius single use bioreactors. The facility also houses a GMP warehouse, and analytical development and quality control (QC) laboratories. The new 7,400 sq ft process development laboratory uses Sartorius single-use technology (SUT) bioreactors from Ambr® 250mL to 2L, 50L and 200L STR bioreactor to screen important process parameters to develop robust scaleable processes and ensure seamless manufacturability. Learn More

Investment group Bridgewest has bought the Adelaide biologics manufacturing plant operated by Pfizer and will develop it into a contract drug and vaccine manufacturer. Pfizer, which operates four Australian factories employing 1,000, sold the Thebarton plant for an undisclosed sum to the tightly-held investment group which founded the BioDuro drug manufacturing operations in the United States and China. The Adelaide facility has product development, commercialisation and manufacturing capability in microbial-based products such as proteins, vaccines, and plasmids. It will continue to be operated by Pfizer subsidiary Hospira Adelaide until the third quarter of 2021, when Bridgewest will take control. Learn More

FUJIFILM Corporation has announced that it is expanding its gene therapy offering with the addition of viral vector process development and GMP manufacturing services at FUJIFILM Diosynth Biotechnologies in Tees Valley. The laboratories will be outfitted with state-of-the-art equipment to support upstream (suspension and adherent) processes, downstream processing and analytical development. The viral vector process development laboratories in the UK will be online from spring 2021 with the GMP manufacturing capabilities expected to be available in the Fall of 2021 and will support bulk drug substance production of investigational drugs used in early-stage clinical trials. Learn More

Firmenich has announced the opening of its new biotechnology and naturals pilot plant and laboratory that is Integrated into the Group's flagship ingredients production site at La Plaine, Geneva, Switzerland. "With our new biotechnology pilot plant closely connected with the ingredients production site, Firmenich provides integrated biotech development all the way down to the finished product, without any gaps," said Genevieve Berger, Chief Research Officer, Firmenich. Harnessing digital technology for increased automation, the pilot plant is able to move from single to continuous batch process, increasing efficiency, speed and reducing the use of raw materials. Learn More

A biotech company that is involved in the federal government's initiative to develop and distribute a COVID-19 vaccine next year might move into a building in Gaithersburg. City officials won't disclose the name of the company, but Assistant City Manager Tom Lonergan told Bethesda Beat that it is involved in Operation Warp Speed - a partnership between federal government agencies to produce more than 300 million doses of the vaccine. The building, at 700 Quince Orchard Road, is in an area of Gaithersburg near multiple biotech companies and adjacent to the National Institute of Standards and Technology campus. Learn More

Adaptive Biotech has celebrated the topping off of its new 100,000 sq. ft. facility being constructed in Seattle, Washington. The site, located at 1165 Eastlake Ave E, is roughly a six-minute walk from the company's current location at 1551 Eastlake Ave which the company plans to retain. Construction of the new building is on schedule to be completed in the latter part of 2021. Adaptive, which spun out of the Fred Hutchinson Cancer Research Center, works closely with Microsoft as part of its long-term quest to diagnose multiple diseases from a single blood test. Learn More

ABEC has announced it is supporting Serum Institute of India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax' COVID-19 vaccine candidate, NVX CoV2373. Serum Institute, the world's largest vaccine manufacturer by number of doses, will utilize ABEC's single-use technologies to advance a global supply of NVX CoV2373 throughout India and low- and middle-income countries. Serum Institute's new facility will be the largest single-use bioreactor-based vaccine manufacturing line in the world.  ABEC's 4,000L CSR single-use bioreactors are the largest in the industry by a factor of two, allowing Serum Institute to double productivity per unit floorspace and achieve the lowest possible cost per dose. Learn More

IQHQ has purchased more than 8 acres of waterfront land to create a life science city along San Diego's Bay. The transaction paves the way for what IQHQ is calling the San Diego Research and Development District, or RaDD, as a massive lab-filled campus where ground-floor retail and unrivaled bay views work to recruit the biggest names in the biopharma industry. IQHQ plans to begin construction on site infrastructure immediately with a stated goal of completing the first phase of the district by the summer of 2023. The overall project, estimated to cost $1.5+ billion includes a series of mid-rise structures and one 17-story tower, as well as a museum, and 3 acres of green space and rooftop decks. Learn More

Catalent has acquired a new manufacturing facility in Bloomington, IN, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services. The $14 million investment includes the acquisition, build-out, and qualification of the 23,000 sq. ft. facility to begin supporting customer programs starting January 2021. The facility, purchased from AB BioTechnologies, will be fully integrated with Catalent Biologics' main Bloomington facility located nearby, where the company recently announced a $50 million investment to install an additional high-speed vial filling line. Learn More

Volastra Therapeutics, a biotech company that works in the development of cancer treatments, has signed a lease for 11,000 sq. ft. of lab space in NYC. The specialized space, located in the Mink Building at West 126thSt. and 1361 Amsterdam Ave, includes a chemical fume hood, vacuum system and autoclave pressure chamber. The lease is structured with the potential for easy expansion and term extension, according to Scott Metzner, principal of Janus Property, which has redevelopment The Mink Building as part of its 1.1 million square feet master planned Manhattanville Factory District. Learn More

Webster developer Galaxy Life Sciences has plans to build a $50-million facility in the Worcester biomanufacturing campus The Reactory, offering the site its second planned building. While Galaxy plans to build this facility without having a tenant lined up Galaxy principal Michael O'Brien and Vice President Matthew Zicaro believe the Massachusetts life sciences industry is so strong, they will have a new tenant lined up in a matter of months. If all goes according to plan, Galaxy can then use this development to build out the rest of the 46-acre Reactory site, creating a biotech cluster in Worcester. Learn More

Breakthrough Properties has announced the lease of the property at 105 W. First St. in Boston, Mass. to CRISPR Therapeutics, a gene editing company. CRISPR will fully occupy the building, dubbed "The 105," which totals 263,500 square feet of office and lab space. Construction of the building began in 2020 and the property is scheduled for delivery in early 2022. It was designed by architecture firm Payette as a best-in-class laboratory building. Currently, CRISPR has R&D facilities in Cambridge, MA as well as offices in San Francisco, CA. No word yet if the company plans to consolidate its operations at the new site. Learn More

Kicking a football through a ceremonial goalpost, Lou Kassa joined with founders and county officials to celebrate the launch of a $19 million expansion of the Pennsylvania Biotechnology Center, a long-awaited project that is expected to bring more than 100 new jobs to the facility after its planned fall 2021 opening. "We've been at full capacity for the past seven years and we have a waiting list of companies that want to locate in the PABC," said Kassa, executive vice president of the PABC and the Blumberg Institute, which manages the center. "At the same time, there will be opportunities for new companies to move into the PABC with our expansion." Learn More

BioNTech is buying a production site for the COVID-19 vaccine it is developing with Pfizer, aiming to boost output by several hundred million doses next year, and hopes to have the shot ready to file for approval in October. It is buying the facility, in the German city of Marburg, from Swiss drugs giant Novartis. The facility will be converted to be fully on stream in the first half of 2021 with an annual production capacity up to 750 million doses of the inoculation. The transaction with Novartis, for which the price tag was not disclosed, is part of a push to prepare for a global roll-out of the pair's experimental vaccine, based on so-called messenger RNA (mRNA) technology. Learn More

Aphena Pharma Solutions, a service provider in the pharmaceutical and biological industries, has announced plans to invest $21 million to expand, renovate and retrofit its operations in Cookeville, Tennessee. The 500,000 sq. ft. renovated facility enable the consolidation of two other sites while enabling growth in biologic packaging, cold chain storage and 3PL distribution services. The project is expected to created 160 new jobs over the next five year. Learn More

Takeda has announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U. and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world. Learn More

Bushu Pharmaceuticals, one of Japan's largest CMO's, has unveiled a major capital program costing $100 million to expand its footprint, capacity and portfolio of services over the next five years. These monies will be used to expand inspection capacity to 12 stations for pre-filled syringes, and seven stations each for liquid vials and for lyophilized vials. Of the 26 inspection stations, 23 will be supported by cameras. Additionally, Bushu has also funded the addition of eight new packaging lines, including one pre-filled packaging line and a new water-for-injection line to support its sterile manufacturing filling suite. Bushu is also upgrading its production automation systems and its laboratory information management system (LIMS). Learn More

Beam Therapeutics has announced that it will invest $83 million and hire 201 employees for its new Research Triangle Park manufacturing facility. The investment, which will occur over a five-year period, will further enable the manufacture of precision medicine. "We believe investment in strategic manufacturing capabilities is an important component of fully realizing the power of our base editing technology and achieving our vision to provide life-long cures to patients suffering from serious diseases", said John Evans, CEO of Beam Therapeutics. The company's project is being facilitated by a Job Development Investment Grant. Learn More

Merck KGaA announced this week that it would invest $69.5 million in expanding its manufacturing capabilities, and capacity for high-potent active pharmaceutical ingredients and antibody-drug conjugates at its U.S. facility near Madison, Wisc. The biopharma company said the investment would allow manufacturing of compounds for therapies which have the potential to treat cancer, and it would create roughly 50 full-time jobs starting in 2021. Completion of the expansion, which consists of a roughly 70,000 square foot commercial building, is expected by mid-2022, the company said. Learn More

Catalent is investing $130 million to bolster manufacturing capacity at its gene therapy campus in Maryland. The company said the site in Harmans will add five Phase III to commercial-scale manufacturing suites, bringing the two state-of-the-art facilities to a total of 15 such suites. Catalent said 10 of the suites are expected to be qualified and operational by the first quarter of 2021, now that the first facility has been approved by the FDA for commercial manufacturing. The new building and its five suites are expected to be operational in the first half of 2022. The new building will also offer cold storage warehousing, office space and more. Learn More

In a recent filing with the SEC, Five Prime Therapeutics has made public the decision to sublease its lab and office space at 111 Oyster Point Blvd in South San Francisco, California. The terms of the deal have Sutro Biopharma initially acquiring 85,755 sq. ft. of the site in April, 2021. The remainder of the site, roughly 29,711 sq. ft., would be occupied some 24 months later. According to the filing the sublease will expire in December, 2027. Alert readers will recall that initial rumors of Five Prime's possible need to sublease the site began circulating in the latter part of 2019. Learn More

Bionova Scientific has initiated construction of its new state-of-the-art biologics manufacturing facility. Construction will be completed in approximately 10 months, with commissioning scheduled for Q3 2021. The 36,000 sq. ft. facility will utilize single-use technologies for all core unit operations and is designed to accommodate two 2000L mammalian cell culture trains, capable of producing clinical and commercial bulk drug substance. Located within Bionova's 56,000 sq. ft. headquarters, the plant is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins. Bionova has partnered with industry leaders DGA and Dome Construction for design and construction. Learn More

Novartis has announced that it is constructing a new production unit for experimental drugs on the outskirts of the city of Basel. The roughly $78 million investment will give it two new production lines. Both will be dedicated to producing active ingredients for experimental medicines. The production lines will be developed in an existing building in the Schweizerhalle industrial area on the outskirts of Basel. These new facilities will be commissioned at the end of next year. This investment confirms the importance of Schweizerhalle as a global production site, Novartis said. Learn More

The developer that owns Hilltop Mall has rebranded the 78-acre property as the East Bay Science and Technology Center and plans to sell or lease it, according to published reports. After purchasing the property in 2017, LBG Real Estate Cos. had planned to modernize the shopping center and construct housing, office space and a hotel on the Hilltop drive property. Those plans have since changed, with the COVID-19 pandemic cited as a contributing factor. The mostly vacant mall, about 16 percent occupied by retailers, is "now looking to offload the asset, pitching it as a new potential center for life sciences and biotech space." Learn More

Regeneron has announced plans to expand operations at its site in Limerick, Ireland adding roughly 400 new jobs. The expansion is a result of a decision to prepare Regeneron's plant in New York to produce a potential new antibody-based treatment for Covid-19, REGN-COV2. The new roles will be in a wide variety of areas, including commercial manufacturing, process sciences, quality assurance/control, supply chain and various support functions for scientists, chemists and technicians. Regeneron has been in Limerick since 2014, when it took over the old Dell factory in the city and has since invested over $1 billion in its campus which became operational in 2015. Learn More

Plans have gone out to consultation to build a 10-storey office and research building for US biopharmaceuticals giant Merck opposite King's Cross station in London. Designed by architect AHMM, the MSD Discovery Hub, is expected to achieve a BREEAM Outstanding rating and will have an innovative biophilic façade incorporated as part of the plan for a carbon-efficient building. The low-rise existing Belgrove House on Euston Road will be demolished to make way for the research building, also incorporating a new London Underground station entrance. Learn More

Bristol Myers Squibb has signed a 360,000 square- foot lease at 250 Water Street in Cambridge Crossing, the new and connected neighborhood at the intersection of Cambridge, Somerville, and Boston. The new building is currently under construction and is expected to be complete in late 2022. Bristol Myers Squibb plans to combine its Cambridge presence at the state-of-the-art laboratory and office building by the end of the first half of 2023. The site is a 43 acre parcel being developed to offer 2.1 million sq. ft. of state-of-the-art science and technology space and includes 11 acres of open space. Learn More

AdvanceTEC has announced that the company has been awarded a contract stemming from "Operation Warp Speed" COVID-19 vaccine initiative to provide fast-track cleanroom integration.  As a part of this project, the company is working with one of the top five identified companies for rapid creation and deployment of a vaccine for COVID-19 Coronavirus. Key to delivering the project is AdvanceTEC's "Cleanroom IP" platform, which leverages in-house proprietary algorithmic technology, and harnesses digital field scanning, 3D BIM / VDC modeling, laser field layout, off-site fabrication and JIT on-site integration for a robust concept to commissioning delivery. Learn More

Merck & Co., known in Europe as MSD to ensure no confusion with Merck of Germany, has made public plans to build a $1.3 Billion research hub in London. The site, which is rumored to be planning to be home to 800 people, will cover an area of roughly 270,000 sq. ft. (25,000 m2). According to published reports, the official name of the site will be the London Discovery Research Center with construction planned to commence in the latter part of next year. The schedule calls for Merck to occupy the site in 2025 with many of the early occupants being drawn from other Merck sites in and around London. Learn More

Galaxy Life Sciences has inked a deal to build an estimated $50 million building on a 6-acre plot at The Reactory biomanufacturing park. The deal also grants Galaxy Life Sciences the right to develop the remainder of the available lots in the biomanufacturing park on the former Worcester State Hospital campus. Galaxy Life Sciences bought the 6-acre parcel at The Reactory from the Worcester Business Development Corp., this week for $1.9 million, according to documents filed at the Worcester Registry of Deeds. This fall the WBDC and the city of Worcester will begin to construct and upgrade the roadway network and all necessary utilities to service the sites at The Reactory. Learn More